成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 13534-97-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 13534-97-9
Chemical Structure| 13534-97-9
Structure of 13534-97-9 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 13534-97-9 ]

Related Doc. of [ 13534-97-9 ]

Alternatived Products of [ 13534-97-9 ]
Product Citations

Product Citations

Jang, Mingyeong ; Lim, Taeho ; Park, Byoung Yong , et al. DOI: PubMed ID:

Abstract: In this study, we developed a metal-free and highly chemoselective method for the reduction of aromatic nitro compounds. This reduction was performed using tetrahydroxydiboron [B2(OH)4] as the reductant and 4,4'-bipyridine as the organocatalyst and could be completed within 5 min at room temperature. Under optimal conditions, nitroarenes with sensitive functional groups, such as vinyl, ethynyl, carbonyl, and halogen, were converted into the corresponding anilines with excellent selectivity while avoiding the undesirable reduction of the sensitive functional groups.

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Product Details of [ 13534-97-9 ]

CAS No. :13534-97-9 MDL No. :MFCD01646116
Formula : C5H5BrN2 Boiling Point : -
Linear Structure Formula :- InChI Key :XTHKRYHULUJQHN-UHFFFAOYSA-N
M.W : 173.01 Pubchem ID :642811
Synonyms :

Calculated chemistry of [ 13534-97-9 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 36.34
TPSA : 38.91 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.5 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.29
Log Po/w (XLOGP3) : 1.2
Log Po/w (WLOGP) : 1.43
Log Po/w (MLOGP) : 0.58
Log Po/w (SILICOS-IT) : 1.41
Consensus Log Po/w : 1.18

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.22
Solubility : 1.03 mg/ml ; 0.00597 mol/l
Class : Soluble
Log S (Ali) : -1.61
Solubility : 4.21 mg/ml ; 0.0243 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.51
Solubility : 0.531 mg/ml ; 0.00307 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.84

Safety of [ 13534-97-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 13534-97-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 13534-97-9 ]
  • Downstream synthetic route of [ 13534-97-9 ]

[ 13534-97-9 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 13534-97-9 ]
  • [ 915006-52-9 ]
YieldReaction ConditionsOperation in experiment
65% With iodine; silver sulfate In ethanol To a stirred solution of 6-bromo-pyridin-3-ylamine (10.2 g, 0.0580 mol) and Ag2SO4 (18.1 g, 0.0580 mol) in EtOH (150 mL) was added 12 (7.59 g, 0.0580 mol) and the reaction was allowed to stir overnight. At this time hexane (200 mL) was added and the resultant mixture was filtered through Celite. The solvent was removed in vacuo, dissolved in CHCl3 (200 mL), washed with aqueous saturated Na2S2O3 (100 mL), water (1.x.100 mL), and dried (Na2SO4). The solvent was concentrated in vacuo and the residue was dissolved in hot EtOAc (100 mL), filtered and treated with hexanes (100 mL). Filtration gave 11.2 g (65percent) of the title compound as a white crystalline material. 1H-NMR (CDCl3; 400 MHz): δ 7.10 (d, 1H, J=8.2 Hz), 6.74 (d, 1H, J=8.2 Hz), 4.06 (br s, 2H).
65% With iodine; silver sulfate In ethanol at 20℃; To a stirred solution of 6-bromo-pyridin-3-ylamine (10.2 g, 0.0580 mol) and Ag2SO4 (18.1 g, 0.0580 mol) in EtOH (150 mL) was added I2 (7.59 g, 0.0580 mol) and the reaction was allowed to stir overnight. At this time hexane (200 mL) was added and the resultant mixture was filtered through Celite. The solvent was removed in vacuo, dissolved in CHCl3 (200 mL), washed with aqueous saturated Na2S2O3 (100 mL), water (1.x.100 mL), and dried (Na2SO4). The solvent was concentrated in vacuo and the residue was dissolved in hot EtOAc (100 mL), filtered and treated with hexanes (100 mL). Filtration gave 11.2 g (65percent) of 6-bromo-2-iodo-pyridin-3-ylamine as a white crystalline material. 1H-NMR (CDCl3; 400 MHz): δ 7.10 (d, 1H, J=8.2 Hz), 6.74 (d, 1H, J=8.2 Hz), 4.06 (br s, 2H).
65% With iodine; silver sulfate In ethanol Example 51; 5-Cyano- lH-imidazole-2-carboxylic acid [2-(dimethyl-cyclohex- 1 -enyl)-6-( 1 -hydroxy- 1 - methyl-ethyl)-pyridin-3-yl]-amide; a) 6-Bromo-2-iodo-pyridin-3-ylamine; <n="112"/>To a stirred solution of 6-bromo-pyridin-3-ylamine (10.2 g, 0.0580 mol) and Ag2SO4 (18.1 g, 0.0580 mol) in EtOH (150 mL) was added I2 (7.59 g, 0.0580 mol) and the reaction was allowed to stir overnight. At this time hexane (200 mL) was added and the resultant mixture was filtered through Celite. The solvent was removed in vacuo, dissolved in CHCl3 (200 mL), washed with aqueous saturated Na2S2O3 (100 mL), water (1 x 100 mL), and dried (Na2SO4). The solvent was concentrated in vacuo and the residue was dissolved in hot EtOAc (100 mL), filtered and treated with hexanes (100 mL). Filtration gave 11.2 g (65 percent) of the title compound as a white crystalline material. 1H- NMR (CDCl3; 400 MHz): δ 7.10 (d, IH, J = 8.2 Hz), 6.74 (d, IH, J = 8.2 Hz), 4.06 (br s, 2H). .
Reference: [1] Patent: US2007/249649, 2007, A1, . Location in patent: Page/Page column 74
[2] Patent: US2007/249608, 2007, A1, . Location in patent: Page/Page column 41
[3] Patent: WO2007/123516, 2007, A1, . Location in patent: Page/Page column 109-110
[4] Patent: WO2009/149820, 2009, A1, . Location in patent: Page/Page column 82-83
[5] Journal of Medicinal Chemistry, 2013, vol. 56, # 21, p. 8860 - 8871
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 13534-97-9 ]

Bromides

Chemical Structure| 1033203-41-6

[ 1033203-41-6 ]

6-Bromopyridine-3,4-diamine

Similarity: 0.87

Chemical Structure| 109-04-6

[ 109-04-6 ]

2-Bromopyridine

Similarity: 0.85

Chemical Structure| 126325-47-1

[ 126325-47-1 ]

6-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 39856-56-9

[ 39856-56-9 ]

6-Bromo-N,N-dimethylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 50786-37-3

[ 50786-37-3 ]

4,6-Dibromopyridin-3-amine

Similarity: 0.80

Amines

Chemical Structure| 1033203-41-6

[ 1033203-41-6 ]

6-Bromopyridine-3,4-diamine

Similarity: 0.87

Chemical Structure| 126325-47-1

[ 126325-47-1 ]

6-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 39856-56-9

[ 39856-56-9 ]

6-Bromo-N,N-dimethylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 50786-37-3

[ 50786-37-3 ]

4,6-Dibromopyridin-3-amine

Similarity: 0.80

Chemical Structure| 39856-57-0

[ 39856-57-0 ]

2,6-Dibromopyridin-3-amine

Similarity: 0.78

Related Parent Nucleus of
[ 13534-97-9 ]

Pyridines

Chemical Structure| 1033203-41-6

[ 1033203-41-6 ]

6-Bromopyridine-3,4-diamine

Similarity: 0.87

Chemical Structure| 109-04-6

[ 109-04-6 ]

2-Bromopyridine

Similarity: 0.85

Chemical Structure| 126325-47-1

[ 126325-47-1 ]

6-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 39856-56-9

[ 39856-56-9 ]

6-Bromo-N,N-dimethylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 50786-37-3

[ 50786-37-3 ]

4,6-Dibromopyridin-3-amine

Similarity: 0.80

; ;